培美曲塞单药维持治疗晚期非小细胞肺癌的临床疗效  

Clinical observations of maintenance chemotherapy by pemetrexed on advanced non-small-cell lung cancer

作　　者：万莉娟[1] 肖丹[1] 

机构地区：[1]江西省肿瘤医院内二科,南昌市330029

出　　处：《实用医学杂志》2015年第15期2553-2555,共3页The Journal of Practical Medicine

摘　　要：目的：观察培关曲塞单药维持治疗晚期非小细胞肺癌的疗效及对生存时间的影响。方法：将60例Ⅲb～Ⅳ期非小细胞肺癌患者随机分为观察者和对照组，两组均接受初期4个周期的诱导化疗，且达到部分缓解或稳定．观察组在完成4个周期化疗后第21天开始应用培美曲塞单药维持治疗直至疾病进展，对照组给予最佳支持治疗。观察无进展生存期（PFS）、总生存期（OS）及不良反应。结果：观察组患者PFS及OS明显高于对照组。PFS分别为（7．3±1．20）vs（3．5±1．13）个月，OS分别为（12．2±1．14）vs（7．1±1．23）个月，差异有统计学意义，且不良反应轻，主要为疲乏和白细胞减少，但患者均可耐受。结论：晚期非小细胞肺癌患者化疗稳定后应用培美曲塞维持治疗能明显延长患者的无进展生存期和总生存期，且不良反应均可耐受。Objective To observe the clinical effect of maintenance chemotherapy by pemetrexed in advanced non-small-eel] lung cancer. Methods 60 patients with advanced non-small-cell lung cancer （stage Ⅲ b -Ⅳ ） were randomly divided into observation group and control group, all the patients showed complete or partialremission after receiving 4 cycles of induction chemotherapy. Observation group was given pemetrexed maintenance （500 mg/m^2 on days 1 every 21 days） until first disease progression, control group was given best supportive care. Progression free survival （PFS）, overall survival （OS） and adverse reaction were observed. Results PFS and OS of observation group were significantly higher than control group, PFS was （7.3 ± 1.20） vs （3.5 ±1.13） months, OS was （12.2 ±1.14） vs （7.1 ± 1.23） months, the difference was statistically significant. The main side effects were fatigue and leucopenia which were tolerable. Conclusion Maintenance therapy with peme- trexed following initial therapy was feasible, and extended the PFS and OS, and shows a favorable toxicity profile.

关 键 词：培美曲塞 维持治疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]